• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.天然化合物及其类似物作为对抗最毒细菌毒素的有效解毒剂。
Appl Environ Microbiol. 2018 Nov 30;84(24). doi: 10.1128/AEM.01280-18. Print 2018 Dec 15.
2
Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A.肉毒杆菌神经毒素A血清型小分子抑制剂的鉴定及生化特性研究
Antimicrob Agents Chemother. 2009 Aug;53(8):3478-86. doi: 10.1128/AAC.00141-09. Epub 2009 Jun 15.
3
Interactions of a potent cyclic peptide inhibitor with the light chain of botulinum neurotoxin A: Insights from X-ray crystallography.一种强效环肽抑制剂与肉毒杆菌神经毒素A轻链的相互作用:来自X射线晶体学的见解
Bioorg Med Chem. 2015 Nov 15;23(22):7264-73. doi: 10.1016/j.bmc.2015.10.024. Epub 2015 Oct 17.
4
Strategies to design inhibitors of Clostridium botulinum neurotoxins.设计肉毒梭菌神经毒素抑制剂的策略。
Infect Disord Drug Targets. 2007 Mar;7(1):47-57. doi: 10.2174/187152607780090667.
5
Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody.人源化抗体对E型肉毒杆菌神经毒素的中和作用。
Toxins (Basel). 2016 Sep 12;8(9):257. doi: 10.3390/toxins8090257.
6
8-Hydroxyquinoline and hydroxamic acid inhibitors of botulinum neurotoxin BoNT/A.肉毒杆菌神经毒素BoNT/A的8-羟基喹啉和异羟肟酸抑制剂
Curr Top Med Chem. 2014;14(18):2094-102. doi: 10.2174/1568026614666141022095114.
7
Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins.天然神经毒素相关蛋白的一种分离成分增强纯化的肉毒杆菌神经毒素A和E的内肽酶活性。
Biochemistry. 2004 Apr 27;43(16):4791-8. doi: 10.1021/bi0355544.
8
Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B.人源化抗B型肉毒杆菌毒素单链抗体片段-抗体融合蛋白的研制
MAbs. 2015;7(6):1161-77. doi: 10.1080/19420862.2015.1082016. Epub 2015 Sep 18.
9
Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library.从猕猴免疫文库中开发抗肉毒杆菌神经毒素A轻链的中和单链抗体片段-免疫球蛋白融合蛋白
MAbs. 2014 Mar-Apr;6(2):446-59. doi: 10.4161/mabs.27773. Epub 2014 Jan 9.
10
Differential endopeptidase activity of different forms of type A botulinum neurotoxin: A unique relationship between the size of the substrate and activity of the enzyme.不同形式的A型肉毒杆菌神经毒素的差异内肽酶活性:底物大小与酶活性之间的独特关系。
Toxicon. 2018 Mar 15;144:34-41. doi: 10.1016/j.toxicon.2017.12.055. Epub 2018 Jan 5.

引用本文的文献

1
Investigating the phenotypic alterations associated with hypermucoviscous hypervirulent Klebsiella pneumoniae during phage resistance development.研究噬菌体抗性发展过程中与高黏液性高毒力肺炎克雷伯菌相关的表型改变。
BMC Microbiol. 2025 Aug 22;25(1):528. doi: 10.1186/s12866-025-04268-x.
2
Use of botulinum toxin in aesthetic medicine and gynaecology: current approaches, controversies, and future directions.肉毒杆菌毒素在美容医学和妇科中的应用:当前方法、争议及未来方向。
Prz Menopauzalny. 2023 Sep;22(3):155-160. doi: 10.5114/pm.2023.131457. Epub 2023 Sep 25.
3
Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update.肉毒毒素和破伤风神经毒素的毒理学和药理学:最新进展。
Arch Toxicol. 2022 Jun;96(6):1521-1539. doi: 10.1007/s00204-022-03271-9. Epub 2022 Mar 25.
4
An Appraisal of Antidotes' Effectiveness: Evidence of the Use of Phyto-Antidotes and Biotechnological Advancements.解毒剂效果评估:植物解毒剂的应用与生物技术进展的证据。
Molecules. 2020 Mar 26;25(7):1516. doi: 10.3390/molecules25071516.

本文引用的文献

1
The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.轻链决定肉毒毒素 A 型亚型的作用持续时间。
mBio. 2018 Mar 27;9(2):e00089-18. doi: 10.1128/mBio.00089-18.
2
Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A.对A型肉毒杆菌神经毒素具有体外、离体和体内疗效的小分子金属蛋白酶抑制剂。
Toxicon. 2017 Oct;137:36-47. doi: 10.1016/j.toxicon.2017.06.016. Epub 2017 Jul 8.
3
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.肉毒杆菌神经毒素:生物学、药理学与毒理学
Pharmacol Rev. 2017 Apr;69(2):200-235. doi: 10.1124/pr.116.012658.
4
A matrix-focused structure-activity and binding site flexibility study of quinolinol inhibitors of botulinum neurotoxin serotype A.A型肉毒杆菌神经毒素喹诺醇抑制剂的基于矩阵的结构活性和结合位点灵活性研究
Bioorg Med Chem Lett. 2017 Feb 1;27(3):675-678. doi: 10.1016/j.bmcl.2016.11.019. Epub 2016 Nov 9.
5
Utilizing Ayurvedic literature for the identification of novel phytochemical inhibitors of botulinum neurotoxin A.利用阿育吠陀文献鉴定新型植物源肉毒神经毒素 A 抑制剂。
J Ethnopharmacol. 2017 Feb 2;197:211-217. doi: 10.1016/j.jep.2016.07.069. Epub 2016 Jul 26.
6
A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.一种合理的方法,用于鉴定非羟肟酸类 HDAC6 选择性抑制剂。
Sci Rep. 2016 Jul 12;6:29086. doi: 10.1038/srep29086.
7
Natural Products to Counteract the Epidemic of Cardiovascular and Metabolic Disorders.对抗心血管和代谢紊乱流行的天然产物。
Molecules. 2016 Jun 22;21(6):807. doi: 10.3390/molecules21060807.
8
Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.抗H型肉毒杆菌神经毒素单克隆抗体的免疫学特性及中和能力
J Infect Dis. 2016 May 15;213(10):1606-14. doi: 10.1093/infdis/jiv770. Epub 2016 Mar 1.
9
Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?为何异羟肟酸酯可能并非最佳的组蛋白去乙酰化酶抑制剂——有些人可能遗忘或宁愿忘却的是什么?
ChemMedChem. 2016 Jan 5;11(1):15-21. doi: 10.1002/cmdc.201500486. Epub 2015 Nov 25.
10
In Vivo Toxicity and Immunological Characterization of Detoxified Recombinant Botulinum Neurotoxin Type A.解毒重组A型肉毒杆菌神经毒素的体内毒性和免疫学特性
Pharm Res. 2016 Mar;33(3):639-52. doi: 10.1007/s11095-015-1816-x. Epub 2015 Nov 3.

天然化合物及其类似物作为对抗最毒细菌毒素的有效解毒剂。

Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.

机构信息

Department of Chemistry and Biochemistry, University of Massachusetts Dartmouth, North Dartmouth, Massachusetts, USA.

Institute of Advanced Sciences, Dartmouth, Massachusetts, USA.

出版信息

Appl Environ Microbiol. 2018 Nov 30;84(24). doi: 10.1128/AEM.01280-18. Print 2018 Dec 15.

DOI:10.1128/AEM.01280-18
PMID:30389764
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6275346/
Abstract

Botulinum neurotoxins (BoNTs), the most poisonous proteins known to humankind, are a family of seven (serotype A to G) immunologically distinct proteins synthesized primarily by different strains of the anaerobic bacterium Being the causative agents of botulism, the toxins block neurotransmitter release by specifically cleaving one of the three soluble -ethylmaleimide-sensitive factor attachment receptor (SNARE) proteins, thereby inducing flaccid paralysis. The development of countermeasures and therapeutics against BoNTs is a high-priority research area for public health because of their extreme toxicity and potential for use as biowarfare agents. Extensive research has focused on designing antagonists that block the catalytic activity of BoNTs. In this study, we screened 300 small natural compounds and their analogues extracted from Indian plants for their activity against BoNT serotype A (BoNT/A) as well as its light chain (LCA) using biochemical and cellular assays. One natural compound, a nitrophenyl psoralen (NPP), was identified to be a specific inhibitor of LCA with an 50% inhibitory concentration (IC) value of 4.74 ± 0.03 µM. NPP was able to rescue endogenous synaptosome-associated protein 25 (SNAP-25) from cleavage by BoNT/A in human neuroblastoma cells with an IC of 12.2 ± 1.7 µM, as well as to prolong the time to the blocking of neutrally elicited twitch tensions in isolated mouse phrenic nerve-hemidiaphragm preparations. The long-lasting endopeptidase activity of BoNT is a critical biological activity inside the nerve cell, as it prompts proteolysis of the SNARE proteins, involved in the exocytosis of the neurotransmitter acetylcholine. Thus, the BoNT endopeptidase activity is an appropriate clinical target for designing new small-molecule antidotes against BoNT with the potential to reverse the paralysis syndrome of botulism. In principle, small-molecule inhibitors (SMIs) can gain entry into BoNT-intoxicated cells if they have a suitable octanol-water partition coefficient (log ) value and other favorable characteristics (P. Leeson, Nature 481:455-456, 2012, https://doi.org/10.1038/481455a). Several efforts have been made in the past to develop SMIs, but inhibitors effective under conditions have not in general been effective or in cellular models (L. M. Eubanks, M. S. Hixon, W. Jin, S. Hong, et al., Proc Natl Acad Sci U S A 104:2602-2607, 2007, https://doi.org/10.1073/pnas.0611213104). The difference between the and cellular efficacy presumably results from difficulties experienced by the compounds in crossing the cell membrane, in conjunction with poor bioavailability and high cytotoxicity. The screened nitrophenyl psoralen (NPP) effectively antagonized BoNT/A in both and assays. Importantly, NPP inhibited the BoNT/A light chain but not other general zinc endopeptidases, such as thermolysin, suggesting high selectivity for its target. Small-molecule (nonpeptidic) inhibitors have better oral bioavailability, better stability, and better tissue and cell permeation than antitoxins or peptide inhibitors.

摘要

肉毒神经毒素(BoNTs)是人类已知的最毒蛋白质,是由七种(血清型 A 到 G)免疫上不同的蛋白质组成,主要由不同的厌氧细菌菌株合成。作为肉毒中毒的致病因子,毒素通过特异性切割三种可溶性 - 乙基maleimide-敏感因子附着受体(SNARE)蛋白之一来阻止神经递质的释放,从而诱导弛缓性瘫痪。由于其极高的毒性和用作生物战剂的潜力,开发针对 BoNTs 的对策和疗法是公共卫生的一个高度优先研究领域。研究集中在设计阻断 BoNTs 催化活性的拮抗剂上。在这项研究中,我们使用生化和细胞测定法筛选了 300 种从小麦印度植物中提取的天然化合物及其类似物,以研究它们对 BoNT 血清型 A(BoNT/A)及其轻链(LCA)的活性。一种天然化合物,硝基苯基补骨脂素(NPP)被鉴定为 LCA 的特异性抑制剂,其 50%抑制浓度(IC)值为 4.74 ± 0.03 μM。NPP 能够以 12.2 ± 1.7 μM 的 IC 值从人神经母细胞瘤细胞中拯救内源性突触相关蛋白 25(SNAP-25)免受 BoNT/A 的切割,并且能够延长分离的小鼠膈神经-半膈肌制备物中中性诱发的抽搐张力的阻断时间。BoNT 的持久内切酶活性是神经细胞内的一种关键生物学活性,因为它促使 SNARE 蛋白的蛋白水解,参与神经递质乙酰胆碱的胞吐作用。因此,BoNT 内切酶活性是设计针对 BoNT 的新型小分子解毒剂的合适临床靶标,具有逆转肉毒中毒瘫痪综合征的潜力。原则上,如果小分子抑制剂(SMIs)具有合适的辛醇-水分配系数(log )值和其他有利特征(P. Leeson,Nature 481:455-456, 2012, https://doi.org/10.1038/481455a),它们可以进入 BoNT 中毒的细胞。过去已经做了一些努力来开发 SMIs,但在 条件下有效的抑制剂通常在 或细胞模型中无效(L. M. Eubanks、M. S. Hixon、W. Jin、S. Hong 等人,Proc Natl Acad Sci U S A 104:2602-2607, 2007, https://doi.org/10.1073/pnas.0611213104)。推测化合物在穿过细胞膜方面遇到困难,以及生物利用度差和细胞毒性高,导致 和细胞功效之间存在差异。筛选出的硝基苯基补骨脂素(NPP)在 测定和细胞测定中均有效地拮抗 BoNT/A。重要的是,NPP 抑制 BoNT/A 轻链,但不抑制其他一般锌内切酶,如耐热素,表明其靶标具有高选择性。小分子(非肽)抑制剂比抗毒素或肽抑制剂具有更好的口服生物利用度、更好的稳定性以及更好的组织和细胞渗透性。